New drug cocktail aims to fight metastatic colorectal cancer
NCT ID NCT06882915
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a combination of three drugs—TAS-102, bevacizumab, and serplulimab—in 20 people with metastatic colorectal cancer who have already had surgery to remove tumors. The goal is to see if the combination is safe and can delay cancer progression. Participants must have failed standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trifluridine/tipiracil (TAS-102) combined with bevacizumab and serplulimab
What this could lead to
If this works, it could offer a new treatment option for people with metastatic colorectal cancer who have not responded to standard therapies, potentially extending survival.
What could go wrong
This is a very early Phase 1 trial with only 20 people, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.